Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
65.42
+0.15 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Via
MarketBeat
Exposures
Product Safety
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
May 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Mount Gilead, NC Author Publishes Children's Book
May 17, 2023
Take In The Beauty Of Nature And Quiet The Outside World.
Via
PR Leap
Gilead Appoints Cindy Perettie Executive Vice President of Kite
May 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
May 15, 2023
From
Arcus Biosciences
Via
Business Wire
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
May 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
May 04, 2023
Via
Investor Brand Network
Exposures
COVID-19
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
May 04, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
May 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
Gilead Sciences to Present at Upcoming Investor Conferences
May 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces First Quarter 2023 Financial Results
April 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
6 Best Healthcare Stocks to Buy Right Now
April 25, 2023
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat.
Via
MarketBeat
Topics
Economy
Intellectual Property
Exposures
Economy
Intellectual Property
Product Safety
Gamida Cell Stock Jumps Over 100% on FDA Approval
April 18, 2023
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo
Via
MarketBeat
Exposures
Product Safety
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
April 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
April 13, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Balm of Gilead’s Manuka Honey Skin Healing Cream Named “Best for Healing Skin Conditions” by US Weekly Magazine
April 07, 2023
Via
Get News
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
March 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
March 22, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
March 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
March 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
March 08, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Topics
Economy
Exposures
Supply Chain
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Completes Acquisition of Tmunity
February 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
February 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
February 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
February 16, 2023
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer...
Via
SBWire
Cholecystitis Treatment Market Demand Trends Outlook Overview Analysis 2022-2029
February 16, 2023
Global Cholecystitis Treatment Market to Witness Huge Growth by Key Players: Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero...
Via
SBWire
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
February 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
February 09, 2023
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)
Via
SBWire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.